Up to 220 million installments of its single dose vaccine against covid-19 will be provided by Johnson & Johnson to the 55 member states of the African Union after the third quarter of 2021, as announced today by the pharmaceutical industry.
At the same time, J&J, through its Janssen Pharmaceutica NV unit, reached an agreement with the African Vaccine Fund (AVAT), which may order an additional 180 million doses.
“We need to immunize at least 60% of our population to eradicate the virus from our continent. “The agreement with J&J helps us move forward with that goal,” said John Enkengasong, director of the African Centers for Disease Control and Prevention.
Earlier this month, Europe approved J&J’s one-size-fits-all vaccine against it coronavirus which has also received approval in the US, Canada and Bahrain, as recalled by AMPE.
At the end of last year, J&J announced that it expected to sign an agreement with the GAVI alliance to offer up to 500 million doses of its vaccine against covid-19 at COVAX, the program supported by the World Health Organization for the distribution of vaccines in poor countries, until 2022.
J&J has set up a global vaccine production and distribution network, working with nine partners on four continents.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
